A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Third Party Open, Multiple Dose Escalation, Single Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered ELX-02 in Independent Consecutive Cohorts of Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2017
At a glance
- Drugs ELX 02 (Primary)
- Indications Cystic fibrosis; Cystinosis; Duchenne muscular dystrophy; Inborn genetic disorders; Mucopolysaccharidosis I; Rett syndrome
- Focus Adverse reactions
- Sponsors Eloxx Pharmaceuticals
- 27 Nov 2017 According to an Eloxx Pharmaceuticals media release, first patient has been dosed, and data are expected at the end of the fourth quarter 2018.
- 10 Oct 2017 Status changed from planning to recruiting.
- 07 Jun 2017 New trial record